Adial Pharmaceuticals announced that it received notice from Nasdaq that the company has regained compliance with Nasdaq Listing Rule 5550, which requires listed companies to maintain stockholders’ equity of at least $2.5M. Nasdaq will continue to monitor the company’s ongoing compliance with the stockholders’ equity requirement and, if at the time of its next periodic report the company does not evidence compliance, it may be subject to delisting.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ADIL:
- Adial Pharmaceuticals Regains Compliance with Nasdaq Listing Requirement
- Adial Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
- Adial Pharmaceuticals files to sell 4.34M shares of common stock for holders
- Adial Pharmaceuticals Chief Medical Officer and Key Opinion Leaders to Discuss “New Aspects in Substance Use Treatment” at The Annual International Society of Addiction Medicine Conference
- Adial Pharmaceuticals hosts KOL webinar on alcohol use disorder